Vaccines

Rabies

Volumn , Issue , 2003, Pages 371-400

  Briggs, Deborah J ^a   Dreesen, David W ^b   Wunner, William H ^c  

^a KANSAS STATE UNIVERSITY   (United States)

^b Lida Corporation   (United States)

^c WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84904027537     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012379077-4/50013-4     Document Type: Chapter

References (141)

1. Abelseth M.K. Propagation of rabies virus in pig kidney cell culture. Can. Vet. J. 1964, 5:84-86.
2. Arai Y.T., Ogata T., Oya A. Studies on Japanese-produced chick embryo cell culture rabies vaccines. Am. J. Trop. Med. Hyg. 1991, 44:131-134.
3. Artois M., Cliquet F., Barrat J., Schumacher C.L. Effectiveness of SAG1 oral vaccine for the long-term protection of red foxes (Vulpes vulpes) against rabies. Vet. Rec. 1997, 140:57-59.
4. Artois M., Guittre C., Thomas I., Leblois H., Brochier B., Barrat J. Potential pathogenicity for rodents of vaccines intended for oral vaccination against rabies: A comparison. Vaccine 1992, 10:524-528.
5. Arya S.C. Transmissible spongiform encephalopathies and sheep-brain-derived rabies vaccines. Biologicals 1994, 22:73.
6. Aubert M.F.A., Masson E., Artois M., Barrat J. Oral wildlife rabies vaccination field trials in Europe, with recent emphasis on France. Cur. Top. Microbiol. Immunol. 1994, 187:219-243.
7. Baer G.M. Evaluation of an animal rabies vaccine by use of two types of potency tests. Am. J. Vet. Res. 1997, 58:837-840.
8. Bahloul C., Jacob Y., Tordo N., Perrin P. DNA-based immunization for exploring the enlargement of immunological cross-reactivity against the lyssaviruses. Vaccine 1998, 16:417-425.
9. Bahmanyar M., Fayaz A., Nour-Salehi S., Mohammadi M., Koprowski H. Successful protection of humans exposed to rabies infection: Post-exposure treatment with the new human diploid cell rabies vaccine and antirabies serum. JAMA 1976, 236:2751-2754.
10. Barth R.K. Rabies in animals. J. Gen. Med. 1994, 6:4.
11. Barth R., Franke V. Retal rhesus monkey lung diploid cell vaccine for humans. Laboratory Techniques in Rabies 1996, 297-300. World Health Organization, Geneva. 4th ed. F.-X. Meslin, M.M. Kaplan, H. Koprowski (Eds.).
12. Barth R., Gruschkau H., Bijok U., Hifenhaus J., Hinz J., Milcke L., Mosier H., Jaeger O., Ronneberger H., Weinmann E. A new inactivated tissue culture rabies vaccine for use in man: Evaluation of PCEC vaccine by laboratory tests. J. Biol. Standard 1984, 12:29-46.
13. Bijok U. Purified chick embryo cell (PCEC) rabies vaccine: A review of the clinical development. Improvements in Rabies Postexposure Treatment 1985, 103-111. Zagreb Institute of Public Health. I. Vodopija, K.G. Nicholson, S. Smerdel, U. Bijok (Eds.).
14. Bingham J., Schumacher C.L., Aubert M.F.A., Hill F.W.G., Aubert A. Innocuity studies of SAG-2 oral rabies vaccine in various Zimbabwean wild non-target species. Vaccine 1997, 15:937-943.
15. Blancou J., Meslin F.-X. Modified live-virus rabies vaccination for oral immunizations of carnivores. Laboratory Techniques in Rabies 1996, 324-337. World Health Organization, Geneva. 4th ed. F.-X. Meslin, M.M. Kaplan, H. Koprowski (Eds.).
16. Briggs D.J., Banzhoff A., Nicolay U., Sirikwin S., Dumavibhat B., Tongswas S., Wasi C. Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified vero cell rabies vaccine. Bull. WHO 2000, 78:693-698.
17. Brochier B., Costy F., Pastoret P.-P. Elimination of fox rabies from Belgium using a recombinant vaccinia-rabies glycoprotein vaccine: An update. Vet. Microbiol. 1995, 46:269-279.
18. Brochier B., Kieny M.P., Costy F., Coppens P., Bauduin B., Lecocq J.P., Languet B., Chappuis G., Desmettre P., Afiademanyo K., Libois R., Pastoret P.-P. Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine. Nature 1991, 354:520-522.
19. Brochier B., Thomas I., Bauduin B., Leveau T., Pastoret P.-P., Languet B., Chappuis B., Desmettre P., Blancou J., Artois M. Use of vaccinia-rabies recombinant virus for the oral vaccination of foxes against rabies. Vaccine 1990, 8:101-104.
20. Bunn T.O. Canine and feline rabies vaccines past and present. The Natural History of Rabies 1991, 415-425. CRC Press, Boca Raton, FL. 2d ed. G.M. Baer (Ed.).
21. Cadoz M., Strady A., Meignier B., Taylor J., Tartaglia J., Paoletti E., Plotkin S. Immunisation with canarypox virus expressing rabies glycoprotein. Lancet 1992, 339:1429-1432.
22. CDC Human rabies prevention-United States, 1991: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbid. Mortal. Weekly Rep. 1991, 40(RR-3):1-14.
23. CDC Human rabies prevention-United States, 1999: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbid. Mortal. Weekly Rep. 1999, 48(RR-1):1-21.
24. Chaloner-Larsson G., Contreras G., Furesz J., Boucher D.W., Krepps D., Humphreys G.R., Mohanna S.M. Immunization of Canadian Armed Forces personnel with live types 4 and 7 adenovirus vaccines. Can. J. Public Health 1986, 77:367-370.
25. Charlton K.M., Artois M., Prevec L., Campbell J.B., Casey G.A., Wandeler A.I., Armstrong J. Oral rabies vaccination of skunks and foxes with a recombinant human adenovirus vaccine. Arch. Virol. 1992, 123:169-179.
26. Chen S.C., Jones D.H., Fynan E.F., Farrar G.H., Clegg J.C., Greenberg D.B., Herrmann J.E. Protective immunity induced by oral immunization with a rotavirus DNA vaccine encapsulated in microparticles. J. Virol. 1998, 72:5757-5761.
27. Chutivongse S., Wilde H., Supich C., Baer G.M., Fishbein D.B. Postexposure prophylaxis for rabies with antiserum and intradermal vaccination. Lancet 1990, 335:896-898.
28. Clark K.A., Wilson P.J. Postexposure rabies prophylaxis and preexposure vaccination failure in domestic animals. J. Am. Vet. Med. Assoc. 1996, 208:1827-1830.
29. Coleman P.G., Dye C. Immunization coverage required to prevent outbreaks of dog rabies. Vaccine 1996, 14:185-186.
30. Compendium of animal rabies vaccines, 2001. J. Am. Vet. Med. Assoc. 2001, 218:26-31.
31. Coulon P., Lafay F., Leblois H., Tuffereau C., Artois M., Blancou J., Benmansour A., Flamand A. The SAG: A new attenuated oral rabies vaccine. Wildlife Rabies Control 1992, 105-111. Wells Medical, Kent. K. Bögel, F.-X. Meslin, M. Kaplan (Eds.).
32. Coulon P., Rollin P.E., Flamand A. Molecular basis of rabies virus virulence: II. Identification of a site on the CVS glycoprotein associated with virulence. J. Gen. Virol. 1983, 64:693-696.
33. Desmettre P., Languet B., Chappuis G., Brochier B., Thomas I., Lecocq J.-P., Kieny M.-P., Blancou J., Aubert M., Artois M., Pastoret P.-P. Use of vaccinia rabies recombinant for oral vaccination of wildlife. Vet. Microbiol. 1990, 23:227-232.
34. Diaz A.M. Suckling-mouse brain vaccine. Laboratory Techniques in Rabies 1996, 243-250. World Health Organization, Geneva. 4th ed. F.-X. Meslin, M.M. Kaplan, H. Koprowski (Eds.).
35. Dietzschold B., Wunner W.H., Wiktor T.J., Lopes A.D., Lafon M., Smith C.L., Koprowski H. Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus. Proc. Natl. Acad. Sci. USA 1983, 80:70-74.
36. Donnelly J.J., Ulmer J.B., Liu M.A. Immunization with DNA. J. Immunol. Methods 1994, 176:145-152.
37. Donnelly J.J., Ulmer J.B., Shiver J.W., Liu M.A. DNA vaccines. Ann. Rev. Immunol. 1997, 15:617-648.
38. Dreesen D.W. Preexposure rabies immunization. Rabies: Guidelines for Medical Professionals 1999, 36-43. Veterinary Learning Systems, Trenton, NJ.
39. Dreesen D.W., Bernard K.W., Parker R.A., Deutsch A.J., Brown J. Immune complex-like disease in 23 persons following a booster dose of rabies human diploid cell vaccine. Vaccine 1986, 4:45-49.
40. Dubielzig R.R., Hawkins K.L., Miller P.C. Mycoplastic sarcoma orginating at the site of rabies vaccination in a cat. J. Vet. Diag. Invest. 1993, 5:637-638.
41. Eng T.R., Fishbein D.B. Epidemiologic factors, clinical findings, and vaccination status of rabies in cats and dogs in the United States in 1988. J. Am. Vet. Med. Assoc. 1990, 197:875-878.
42. Esposito J.J., Knight J.C., Shaddock J.H., Novembre F.J., Baer G.M. Successful oral rabies vaccination of raccoons with raccoon poxvirus recombinants expressing rabies virus glycoprotein. Virology 1988, 165:313-316.
43. Fekadu M., Nesby S.L., Shaddock J.H., Schumacher C.L., Linhart S.B., Sanderlin D.W. Immunogenicity, efficacy, and safety of an oral rabies vaccine (SAG-2) in dogs. Vaccine 1996, 14:465-468.
44. Fedadu M., Summer J.W., Shaddock J.H., Sanderlin D.W., Baer G.M. Sickness and recovery of dogs challenged with a street rabies virus after vaccination with a vaccinia virus recombinant expressing rabies virus N protein. J. Virol. 1992, 66:2601-2604.
45. Fenji P. Propagation of rabies virus in a culture of hamster kidney cells. Can. J. Microbiol. 1960, 6:479-483.
46. Ferguson M., Seagrott V., Schild G.C. A collaborative study on the use of single immunodiffusion for the assay of rabies glycoprotein. J. Biol. Standard 1984, 12:283-294.
47. Fishbein D.B., Baer G.M. Animal rabies: Implications for diagnosis and human treatment. Ann. Intern. Med. 1988, 109:935-937.
48. Forg P., von Hoegen P., Dalemans W., Schirrmacher V. Superiority of the ear pinna over muscle tissue as site for DNA vaccination. Gene Ther. 1998, 5:789-797.
49. Friedberger E., Frohner E. Friedberger and Frohner's Veterinary Pathology 1904, Vol. 1. Hurst and Blackett, London. 4th ed.
50. Fuenzalida E., Palacios R. Un método mejorado en la preparaciün de la vacuna antirábica. Bol. Inst. Bacteriol. Chile 1955, 8:3-10.
51. Fujii H., Takita-Sonoda Y., Mifune K., Hirai K., Nishizono A., Mannen K. Protective efficacy in mice of post-exposure vaccination with vaccinia virus recombinant expressing either rabies virus glycoprotein or nucleoprotein. J. Gen. Virol. 1994, 75:1339-1344.
52. Geison G.L. Pasteur, Roux, and rabies: scientific versus clinical mentalities. J. Hist. Med. 1990, 45:341-365.
53. Germain R.N. MHC-dependent antigen processing and peptide presentation: Providing ligands for lymphocyte activation. Cell 1994, 76:287-299.
54. Greene C.E., Dreesen D.W. Rabies. Infectious Diseases of the Dog and Cat 1998, 114-126. W.B. Saunders, Philadelphia. 2nd ed. C.E. Greene (Ed.).
55. Hanlon C.A., Rupprecht C.E. The reemergence of rabies. Emerging Infections 1998, 59-80. ASM Press, Washington. W.M. Schield, D. Armstrong, J.M. Hughes (Eds.).
56. Haupt W. Rabies-Risk of exposure and current trends in prevention of human cases. Vaccine 1999, 17:1742-1749.
57. Hemachudha T., Griffin D.E., Giffels J.J., Johnson R.T., Moser A.B., Phanuphak P. Myelin basic protein as an encephalitogen in encephalomyelitis and polyneuritis following rabies vaccination. New Engl. J. Med. 1987, 316:369-373.
58. Hendrick M.J., Shafer F.S., Goldschmidt M.H., Haviland J.C., Schelling S.H., Engler S.J., Gliatto J.M. Comparison of fibrosarcomas that developed at vaccination sites and at non-vaccination sites in cats: 239 cases (1991-1992). J. Am. Vet. Med. Assoc. 1994, 205:1425-1429.
59. Hooper D.C., Pierard I., Modelska A., Otvos L., Fu Z.F., Koprowski H., Dietzschold B. Rabies ribonucleocapsid as an oral immunogen and immunological enhancer. Proc. Natl. Acad. Sci. USA 1994, 91:10908-10912.
60. Irsara A., Bressan G., Mutinelli F. Sylvatic rabies in Italy: Epidemiology. J. Vet. Med. 1990, B37:53-63.
61. Jay M.T., Reilly K.F., DeBess E.E., Haynes E.H., Bader D.R., Barrett L.R. Rabies in a vaccinated wolf-dog hybrid. J. Am. Vet. Med. Assoc. 1994, 205:1729-1732.
62. Johnson W.B., Walden M.B. Results of a national survey of rabies control procedures. J. Am. Vet. Med. Assoc. 1996, 208:1667-1672.
63. Jones D.H., Corris S., McDonald S., Clegg J.C., Farrar G.H. Poly(dl-lactide-CO-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration. Vaccine 1997, 15:814-817.
64. Kass P.H., Barnes W.G., Spangler W.L., Chomel B.B., Culbertson M.R. Epidemiologic evidence for casual relation between vaccination and fibrosarcoma tumorigenisis in cats. J. Am. Vet. Med. Assoc. 1993, 203:396-405.
65. Kieny M.-P., Lathe R., Drillien R., Spehner D., Skory S., Schmitt D., Wiktor T., Koprowski H., Lecocq J.P. Expression of rabies virus glycoprotein from a recombinant vaccinia virus. Nature 1984, 312:163-166.
66. Koprowski H., Cox H.R. Studies on chick embryo adapted rabies virus: I. Culture characteristics and pathogenicity. J. Immunol. 1948, 60:533-536.
67. Koprowski H., Black J., Nelson D.J. Studies on chick-embryo-adapted rabies virus: VI. Further changes in pathogenic properties following prolonged cultivation in the developing chick embryo. J Immunol. 1954, 72:94-97.
68. Koprowski H., Yusibov V. The green revolution: Plants as heterologous expression vectors. Vaccine 2001, 19:2735-2741.
69. Krebs J.W., Rupprecht C.E., Childs J.E. Rabies surveillance in the United States during 1996. J. Am. Vet. Med. Assoc. 1997, 211:1525-1539.
70. Berne. Vaccine 1994, 12:317-320.
71. Leblois J., Flamand A. Studies on pathogenicity in mice of rabies virus strains used for oral vaccination of foxes in Europe. Vaccination to Control Rabies in Foxes 1988, 101-104. Commission of the European Communities, Luxumbourg. P.P. Pastoret, B. Brochier, I. Thomas, J. Blancou (Eds.).
72. LeBlois H., Tuffereau C., Blancou J., Artois M., Aubert A., Flamand A. Oral immunization of foxes with avirulent rabies virus mutants. Vet. Microbiol. 1990, 23:259-266.
73. Lépine P., Atanasiu P., Gamet A., Vialat C. Phenolized, freeze-dried sheep brain vaccine: B. Method used at the Pasteur Institute, Paris. Laboratory Techniques in Rabies 1973, 223-233. World Health Organization, Geneva. 3d ed. M.M. Kaplan, H. Koprowski (Eds.).
74. Lodmell D.L., Ewalt L.C. Post-exposure DNA vaccination protects mice against rabies virus. Vaccine 2001, 19:2468-2473.
75. Lodmell D.L., Ray N.B., Ewalt L.C. Gene gun particle-mediated vaccination with plasmid DNA confers protective immunity against rabies virus infection. Vaccine 1998, 16:115-118.
76. Lodmell D.L., Ray N.B., Parnell M.J., Ewalt L.C., Hanlon C.A., Shaddock J.H., Sanderlin D.S., Rupprecht C.E. DNA immunization protects nonhuman primates against rabies virus. Nature Med. 1998, 4:949-952.
77. Martino A.D. Transmissible spongiform encephalopathies and the safety of naturally derived biologicals. Biologicals 1993, 21:61-66.
78. McGarvey P.B., Hammond J., Denelt M.M., Hooper D.C., Fu Z.Z., Dietzschold B., Koprowski H., Michaels F.H. Expression of the rabies virus glycoprotein in transgenic tomatoes. Biotechnology 1995, 13:1484-1487.
79. Meslin F.X., Kaplan M.M. General considerations in the production and use of brain-tissue and purified chicken-embryo rabies vaccines for human use. Laboratory techniques in rabies 1973, 204-212. World Health Organization, Geneva. 4th ed. F.-X. Meslin, M.M. Kaplan, H. Koprowski (Eds.).
80. Mitmoonpitak C., Wilde H., Tepsumetanon W. Current status of animal rabies in Thailand. J. Vet. Med. Sci. 1997, 59:457-460.
81. Modelska A., Dietzschold B., Sleysh N., Fu Z.F., Steplewski K., Hooper D.C., Koprowski H., Yusibov V. Immunization against rabies with plant-derived antigen. Proc. Natl. Acad. Sci. USA 1998, 95:2481-2485.
82. Nicholson K.G. Cell-culture vaccines for human use: general considerations. Laboratory Techniques in Rabies 1996, 271-279. World Health Organization, Geneva. 4th ed. F.-X. Meslin, M.M. Kaplan, H. Koprowski (Eds.).
83. Niezgoda M., Briggs D.J., Shaddock J.H., et al. Pathogenesis of experimentally induced rabies in the domestic ferret. Am. J. Vet. Res. 1997, 58:1327-1331.
84. Nogueira Y.L. Adverse effect versus quality control of the Fuenzalida-Palacios antirabies vaccine. Rev. Inst. Med. Trap. São Paulo 1998, 40:295-299.
85. Pan American Health Organization/World Health Organization XI Inter-American Meeting, at the Ministerial Level, on Animal Health: Regional program for the elimination of human rabies transmitted by dogs in the Americas: Analysis of progress 1990-1998 1999, 13-15. World Health Organization, Geneva.
86. Pan American Health Organization/World Health Organization XI Inter- American Meeting, at the Ministerial Level, on Health and Agriculture: Report of the VIII meeting of directors of national rabies control programs in Latin American (REDIPRA) 2001, World Health Organization, Geneva.
87. Pastore P.P., Frisch R., Blancou J., Wolff F., Brochier B., Schneider L.G. Campagne internationale de vaccination antirabique du renard par voie orale menée au grand-duché de Luxembourg, en Belgique et an France. Ann. Med. Vet. 1987, 131:441-447.
88. Perrin P., Jacob Y., Aquilar-Sétien A., Loza-Rubio E., Jallet C., Desmézières E., Aubert M., Cliquet F., Tordo N. Immunization of dogs with a DNA vaccine induces protection against rabies virus. Vaccine 2000, 18:479-486.
89. Perrin P., Madhusudana S., Gontier-Jallet C., Petres S., Tordo N., Merten O.-W. An experimental rabies vaccine produced with a new BHK-21 suspension cell culture process: Use of serum-free medium and perfusion- reactor system. Vaccine 1995, 13:1244-1250.
90. Perrin P., Morgeaux S., Sureau P. In vitro rabies vaccine potency appraisal by ELISA: Advantages of the immunocapture method with neutralizing anti-glycoprotein monoclonal antibody. Biologicals 1990, 18:321-330.
91. Petronek G.J. Free roaming and feral cats: Their impact on wildlife and human beings. J. Am. Vet. Med. Assoc. 1998, 212:218-226.
92. Plotkin S.A. Rabies vaccine prepared in human cell cultures: Progress and perspectives. Rev. Infect. Dis. 1980, 2:433-448.
93. Plotkin S.A., Rupprecht C.R., Koprowski H. Rabies vaccine. Vaccines 1999, 743-766. W. B. Saunders, Philadelphia. 3d ed. S.A. Plotkin, W.A. Orenstein (Eds.).
94. Precausta P., Soulebot J.-P. Vaccines for domestic animals. The Natural History of Rabies 1991, 445-459. CRC Press, Boca Raton, FL. 2d ed. G.M. Baer (Ed.).
95. Prevec L., Campbell J.B., Christie B., Belbeck L., Graham F.L. A recombinant human adenovirus vaccine against rabies. J. Infect. Dis. 1990, 161:27-30.
96. Ray N.B., Ewalt L.C., Lodmell D.L. Nanogram quantities of plasmid DNA encoding the rabies virus glycoprotein protect mice against lethal rabies virus infection. Vaccine 1997, 15:892-895.
97. Reculard P. Cell-culture vaccines for veterinary use. Laboratory Techniques in Rabies 1996, 314-323. World Health Organization, Geneva. 4th ed. F.-X. Meslin, M.M. Kaplan, H. Koprowski (Eds.).
98. Roman M., Martin-Orozco E., Goodman J.S., Nguyen M.D., Sato Y., Ronaghy A., Kornbluth R.S., Richman D.D., Carson D.A., Raz E. Immunostimulatory DNA sequences junction as T helper-1-promoting adjuvents. Nature Med. 1997, 3:839-854.
99. Rooijakkers E.J., Uittenbogaard J.P., Groen J., Osterhous A.D. Rabies vaccine potency control: Comparison of ELISA systems for antigenicity testing. J. Virol. Methods 1996, 58:111-119.
100. Rupprecht C.E., Hamir A.N., Johnston D.H., Koprowski H. Efficacy of vaccinia-rabies glycoprotein recombinant virus vaccine in raccoons (Procyon lotor). Rev. Infect. Dis. 1988, 10(Suppl. 4):S803-S809.
101. Rupprecht C.E., Wiktor T.J., Johnston D.H., Hamir A.N., Dietzschold B., Wunner W.H., Glickman L.T., Koprowski H. Oral immunization and protection of raccoons (Procyon lotor) with a vaccinia-rabies glycoprotein recombinant virus vaccine. Proc. Natl. Acad. Sci. USA 1986, 83:7947-7950.
102. Sato Y., Roman M., Tighe G., Lee D., Corr M., Nguyen M.D., Silverman G.J., Lotz M., Carosn D.A., Raz E. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996, 273:352-354.
103. Schoenig H.W. Experimental studies with killed canine rabies vaccine. J. Am. Vet. Med. Assoc. 1930, 76:25-27.
104. Seif I., Coulon P., Rollin P.E., Flamand A. Rabies virus virulence: Effect on pathogenicity and sequence characterization of mutations affecting antigenic site III of the glycoprotein. J. Virol. 1985, 53:926-935.
105. Seligmann E.B. Potency tests requirements of the United States National Institutes of Health (NIH). Laboratory Techniques in Rabies 1973, 279-289. World Health Organization, Geneva. 3d ed. M.M. Kaplan, H. Koprowski (Eds.).
106. Singh S., Kumar T.A. Rabies vaccines: An overview. J. Assoc. Prevent. Rabies India 1999, 1:14-20.
107. Sizaret P. General considerations in testing the safety and potency of rabies vaccines. Laboratory Techniques in Rabies 1996, 355-359. World Health Organization, Geneva. 4th ed. F.-X. Meslin, M.M. Kaplan, H. Koprowski (Eds.).
108. Smith J.S., Seidel H.D. Rabies: A new look at an old disease. Prog. Med. Virol. 1993, 40:82-106.
109. Streatfield S.J., Jilka J.M., Hood E.E., Turner D.D., Bailey M.R., Mayor J.M., Woodward S.L., Beifuss K.K., Horn M.E., Delaney D.E., Tizard I.R., Howard J.A. Plant-based vaccines: Unique advantages. Vaccine 2001, 19:2742-2748.
110. Taylor J., Trimarchi C., Weinberg R., Languet B., Guillemin F., Desmettre P., Paoletti E. Efficacy studies on a canarypox-rabies recombinant virus. Vaccine 1991, 9:190-193.
111. Taylor J., Weinberg R., Languet B., Desmettre P., Paoletti E. Recombinant fowlpox virus inducing protective immunity in non-avian species. Vaccine 1988, 6:497-503.
112. Tims T., Briggs D.J., Davis R.D., Moore S.M., Xiang Z., Ertl H.C.J., Fu Z.F. Adult dogs receiving a rabies booster dose with a recombinant adenovirus expressing rabies virus glycoprotein develop high titer of neutralizing antibodies. Vaccine 2000, 18:2804-2807.
113. Code of Federal Regulations Rabies vaccine, killed virus 2000, 602-604. U.S. Government Printing Office, Washington, Title 9, Part 113.209.
114. Tordo N. Characteristics and molecular biology of the rabies virus. Laboratory Techniques in Rabies 1996, 28-51. World Health Organization, Geneva. 4th ed. F.-X. Meslin, M.M. Kaplan, H. Koprowski (Eds.).
115. Tuffereau C., Leblois H., Bennejean J., Coulon P., Lafay F., Flamand A. Arginine or lysine in position 333 of ERA and CVS glycoprotein is necessary for rabies virulence in adult mice. Virology 1989, 172:206-212.
116. Wandeler A.I., Matter H.C., Kappeler A., Budde A. The ecology of dogs and canine rabies: A selective review. Rev. Sci. Technol. Off. Int. Epiz. 1993, 12:51-71.
117. Wanderlie P.S. An improved method for the in vivo efficacy testing of rabies vaccine in mice. Ph.D. thesis 1992, University of Georgia, Athens, GA.
118. Wang Y., Xiang Z., Pasquini S., Ertl H.C.J. The use of an E1-deleted, replicative-defective adenovirus recombinant expressing the rabies virus glycoprotein for early vaccination of mice against rabies virus. J. Virol. 1997, 71:3677-3683.
119. Wiktor T.J., Macfarlan R.I., Dietzschold B., Rupprecht C., Wunner W.H. Immunogenic properties of vaccinia recombinant virus expressing the rabies glycoprotein. Ann. Inst. Pasteur Virol. 1985, 136E:405-411.
120. Wiktor T.J., Macfarlan R.I., Reagan K.J., Dietzschold B., Curtis P.J., Wunner W.H., Kieny M.-P., Lathe R., Lecocq J.P., Mackett M., Moss B., Koprowski H. Protection from rabies by a vaccinia recombinant containing the rabies virus glycoprotein gene. Proc. Natl. Acad. Sci. USA 1984, 81:7194-7198.
121. Wiktor T.J., Sokol F., Kuwert E., Koprowski H. Immunogenicity of concentrated and purified rabies vaccine of tissue culture origin. Proc. Soc. Exp. Biol. Med. 1969, 131:799-805.
122. Wilson P.J., Clark K.A. Postexposure rabies prophylaxis protocol for domestic animals and epidemiologic characteristics of rabies vaccination failures in Texas: 1995-1999. J. Am. Vet. Med. Assoc. 2001, 218:522-525.
123. Winkler W.G., Shaddock J.H., Williams L.W. Oral rabies vacccine: Evaluation of its infectivity I three species of rodents. Am. J. Epidemiol. 1976, 104:294-298.
124. Wold W.S.M., Gooding L.R. Region E3 of adenovirus: A cassette of genes involved in host immunosurveillance and virus-cell interactions. Virology 1991, 184:1-8.
125. World Health Organization Expert Committee on Rabies Sixth report. WHO Technical Report Series No. 523 1973, WHO, Geneva.
126. World Health Organization Expert Committee on Biological Standardization Thirty-First Report. Requirements for Rabies Vaccine for Human Use. WHO Technical Report Series No. 658 1981, WHO, Geneva.
127. World Health Organization Expert Committee on Rabies Seventh Report. WHO Technical Report Series No. 709 1984, WHO, Geneva.
128. World Health Organization Expert Committee on Rabies Eighth Report. WHO Technical Report Series No. 824 1992, WHO, Geneva.
129. World Health Organization Expert Committee on Biological Standardization Forty-Third Report. WHO Technical Report Series No. 840 1994, WHO, Geneva.
130. World Health Organization Report of visits to South Africa, Zimbabwe, Mozambique, Malawi, Zambia from 30 September to 9 November 1997 and Uganda and Tanzania from 24 November to 15 December 1997 in relation to rabies. ZDI/98.5 1998, WHO, Geneva.
131. World Health Organization World survey of rabies for the year 1998. No. 34. WHO/CDS/CSR/APH/99.6 2000, WHO, Geneva.
132. Xiang Z.Q., Ertl H.C.J. Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines. Immunity 1995, 2:129-135.
133. Xiang Z.Q., He Z., Wang Y., Ertl H.C.J. The effect of interferon-γ on genetic immunization. Vaccine 1997, 15:896-898.
134. Xiang Z.Q., Spitalnik S., Cheng J., Erikson J., Wojczyk B., Ertl H.C.J. Immune responses to nucleic acid vaccines to rabies virus. Virology 1995, 209:569-579.
135. Xiang Z.Q., Spitalnik S., Tran M., Wunner W.H., Cheng J., Ertl H.C.J. Vaccination with a plasmid vector carrying the rabies virus glycoprotein gene induces protective immunity against rabies virus. Virology 1994, 199:132-140.
136. Xiang Z.Q., Yang Y., Wilson J.M., Ertl H.C.J. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology 1996, 219:220-227.
137. Yang Y., Ertl H.C.J., Wilson J.M. MHC class I-restricted cytotoxic T-lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses. Immunity 1994, 1:433-442.
138. Yusibov V., Koprowski H. Plants as vectors for biomedical products. J. Med. Food 1998, 1:5-12.
139. Yusibov V., Modelska A., Steplewski K., Agadjanyan M., Weiner D., Hooper D.C., Koprowski H. Antigens produced in plants by infection with chimeric plant viruses immunize against rabies virus and HIV-1. Proc. Natl. Acad. Sci. USA 1997, 94:5784-5788.
140. Yusibov V., Shivprasad S., Turpen T.H., Dawson W., Koprowski H. Plant viral vectors based on tobamoviruses. Curr. Topics Microbiol. Immunol. 1999, 240:81-94.
141. Zoonoses control. WHO Weekly Epidemiol. Rec. 1997, 35:266-267.